Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 1499

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 14
Chunk 1499
---
, between MIRA Pharmaceuticals, Inc. and Bay Shore Trust (incorporated by reference to Exhibit
    10.11 to Form S-1 filed July 28, 2023).
  
    10.12
     
    Agreement
    for Shared Lease Costs, dated April 1, 2023, between MIRA Pharmaceuticals, Inc., Telomir Pharmaceuticals, Inc., and MIRALOGX LLC
    (incorporated by reference to Exhibit 10.12 to Form S-1 filed July 28, 2023).

86

    10.13
     
    Exclusive
    License Agreement, by and between the Company and MIRALOGX, dated as of November 30, 2023 (incorporated by reference to Exhibit 10.1
    to the Current Report on Form 8-K filed November 20, 2023).
  
    10.14
     
    Promissory
    Note and Loan Agreement, by and between the Company and MIRALOGX, dated as of November 15, 2023 (incorporated by reference to Exhibit
    10.3 to the Current Report on Form 8-K filed November 20, 2023).
  
    10.15
     
    Amended and Restated Employment Agreement, dated June 2, 2024, by and between MIRA Pharmaceuticals, Inc. and Michelle Yanez (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed June 28, 2024).
  
    10.16
     
    At The Market Agreement, dated August 12, 2024, by and between MIRA Pharmaceuticals, Inc. and Rodman & Renshaw LLC (incorporated by reference to Exhibit 1.2 of the Company’s Form S-3 filed on August 12, 2024).
  
    10.17
     
    Amendment to Employment Agreement, dated May 28, 2024, between MIRA Pharmaceuticals and Erez Aminov (incorporated by reference to Exhibit 10.10 of the Company’s Form 10-Q filed on August 13, 2024).
  
    14.1
     
    Code
    of Business Conduct and Ethics (incorporated by reference to Exhibit 14.1 to Form S-1 filed July 28, 2023).